GlassScriptPhysician profile
Matthew Ryan Mcfarlane
NPI 1952763641
$1,156.35
in general payments reported to CMS, 2019-2025
28 companies · $639 in 2025
The $639 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $273 · 2023: $116 · 2024: $127 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $192.50 | 2022 | |
| Ucb, INC. | $120.55 | 2024-2025 | Rystiggo, Fintepla |
| Jazz Pharmaceuticals INC. | $91.09 | 2025 | |
| Medtronic, INC. | $65.28 | 2023 | Signia |
| Biogen, INC. | $64.88 | 2025 | Tysabri, Spinraza |
| Tempus Ai, INC | $55.05 | 2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $52.03 | 2025 | |
| Vanda Pharmaceuticals INC. | $45.85 | 2024-2025 | Ponvory |
| Abbvie INC. | $41.80 | 2024-2025 | |
| Csl Behring | $38.80 | 2025 | Hizentra |
| Eisai INC. | $37.56 | 2025 | |
| Merck Sharp & Dohme LLC | $32.90 | 2022-2024 | Keytruda |
| Catalyst Pharmaceuticals, INC. | $30.75 | 2025 | |
| Siemens Medical Solutions USA, INC. | $28.74 | 2022 | |
| Progenics Pharmaceuticals, INC. | $28.40 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $26.40 | 2025 | |
| Neurocrine Biosciences, INC. | $25.46 | 2025 | |
| Acadia Pharmaceuticals INC | $22.50 | 2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $18.53 | 2023 | Lyvispah |
| Boston Scientific Corporation | $17.90 | 2023 | Spaceoar Vue System - 10ml |
| Tonix Medicines, INC. | $16.36 | 2025 | Zembrace Symtouch |
| Axsome Therapeutics, INC. | $16.34 | 2025 | Sunosi |
| Alnylam Pharmaceuticals INC. | $16.22 | 2024 | Amvuttra |
| Mallinckrodt Hospital Products INC. | $15.40 | 2024 | Acthar |
| Argenx US, INC. | $15.22 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Karyopharm Therapeutics INC. | $14.28 | 2023 | Xpovio |
| Lilly USA, LLC | $13.60 | 2025 | Kisunla |
| Myovant Sciences INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.